ClinicalTrials.gg
Enrolling by invitationNCT07102667Updated Aug 11, 2025

The Optimal Protein Intake to Enhance Muscle Mass in Elderly Patients With Pre-dialysis Chronic Kidney Disease

An interventional study of Protein intake 1.2 g/kg/day and resistance exercise and Protein intake 1.0 g/kg/day and resistance exercise in Sarcopenia and Chronic Kidney Disease, sponsored by Chulalongkorn University. Enrolling by invitation at 1 site in Thailand. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Chulalongkorn University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Sarcopenia with a site in Thailand — 6 open to participants now, 6 under way, 1 of them phase 3. Sarcopenia · Thailand.

Started
2025
the only one that year
No phase
6 of 12
3 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Chulalongkorn University

Among the 12 studies in Sarcopenia with a site in Thailand, this one is the only one that started in 2025, is one of 6 with no phase, and was the 10th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

6 of the 12 studies in Sarcopenia with a site in Thailand are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Sarcopenia with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether increasing protein intake in elderly adults with pre-dialysis chronic kidney disease, in combination with resistance exercise, improves muscle mass without worsening renal function.The main questions it aims to answer are:

  • Does a protein intake of 1.2 g/kg BW/day combined with exercise improve muscle mass better than a protein intake of 1.0 g/kg BW/day?
  • Does a protein intake of 1.2 g/kg BW/day combined with exercise lead to greater improvements in muscle strength and function?
  • Does a protein intake of 1.2 1.2 g/kg BW/day combined with exercise cause a decline in renal function (eGFR) compared to a protein intake of 1.0 1.2 g/kg BW/day?

Researchers will compare a group assigned to intake 1.2 g/kg BW/day of protein with another group assigned to intake 1.0 g/kg BW/day, to assess whether the higher intake improves muscle mass and physical performance without causing harm.

Participants will

  • be assessed for body composition, physical performance and nutritional intake.
  • be assigned to consume protein at either 1.2 or 1.0 g/kg/day.
  • perform a home-based resistance exercise program using resistance bands.
  • provide blood and urine sample to monitor renal function.
  • visit the clinic at weeks 12 and 24 for repeated measurement.
03

Conditions studied

  • Sarcopenia
  • Chronic Kidney Disease

Keywords

  • Sarcopenia
  • Chronic kidney disease
  • Protein intake
  • Nutrition
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Thai adults aged ≥ 65 years
  • Chronic kidney disease with estimated (eGFR) 30-59 ml/min/1.73 m2
  • Sarcopenia or presarcopenia (diagnosis based on Asian Working Group for Sarcopenia (AWGS) 2019 definition)

Exclusion criteria

Exclusion Criteria:

  • Active cardiopulmonary disease(s) or uncontrolled hypertension with to resistance training
  • Physically or cognitively unable to participate in the resistance exercise program (e.g. dementia), as determined by the attending physician
  • Limitations of body measurements and interpretation using Bioelectrical Impedance Analysis (BIA) e.g. presence of pacemaker, surgical metal implants
  • Meets the definition of AKI or AKD, defined as alterations in kidney function within the past 3 months
  • Severe vitamin D deficiency (25-OH Vitamin D level \< 10 ng/mL)
  • Refuses to give consent to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Protein intake of 1.2 g/kg/day

    Behavioral: Protein intake 1.2 g/kg/day and resistance exercise

  • Active comparator
    Protein intake of 1.0 g/kg/day

    Behavioral: Protein intake 1.0 g/kg/day and resistance exercise

Interventions

  • BehavioralProtein intake 1.2 g/kg/day and resistance exercise

    Protein intake of 1.2 g/kg/day in combination with resistance exercise using resistance bands

  • BehavioralProtein intake 1.0 g/kg/day and resistance exercise

    Protein intake 1.0 g/kg/day in combination with resistance exercise using resistance bands

06

What researchers measure

Primary outcomes

  1. Between-Group Differences in Muscle Mass Changes at 6 Months

    Time frame: From enrollment to the end of intervention at 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 12 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 5, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07102667
Responsible party
Chawalya Angsuwatjarakorn, MD (Principal Investigator, Chulalongkorn University) — Principal investigator
First posted
Aug 5, 2025
Start date
Jun 1, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion